openPR Logo
Press release

MEDIA ADVISORY 4/3 "It Starts with Sylvan" Donates $1,000 towards 2012 Walk to End Alzheimer's

04-05-2012 04:17 AM CET | Associations & Organizations

Press release from: Alzheimer's Association Long Island

/ PR Agency: PRMG
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Association Long Island
Patty Gorman, Team Captain, It Starts With Sylvan

What: In support of the 2012 Walk to End Alzheimer’s, It Starts With Sylvan — a group of students at Sylvan Avenue Elementary School — will present Alzheimer’s Association Long Island with a check in the amount of $1,000 to benefit the Walk, which will take place on September 8 at Old Bethpage Village Restoration.

Students helped raise money during the month of March by purchasing AALI awareness ribbons for a donation. In addition, peer leaders sold Alzheimer’s awareness pens, shoelaces, backpack tags and bracelets to students at the school’s “Awareness Shop.” They also wrote letters to their “Grandpals” who reside at Atria Senior Living Facility.

There are 5.4 million people in the U.S. who are afflicted with Alzheimer’s. Of that number, 60,000 live here on Long Island. In the coming years, the Association expects to see a drastic increase in these numbers if a cure is not found. Currently, one in eight people over the age of 65 have Alzheimer’s disease.

When: Tuesday, April 3

8:30 a.m.

Where: Sylvan Avenue Elementary School

600 Sylvan Avenue

Bayport, NY

Directions: From the LIE: Exit 62 toward Blue Point/Nicolls Road/Stony Brook: Take Nicolls Road (CR 97) towards Blue Point. Go half a mile, then turn right onto Purick Street. After 4.6 miles, turn left onto Sylvan Avenue. School will be on the right.

From Sunrise Highway (Route 27): Exit 51 toward Blue Point/Stony Brook/Nicolls Road. Take ramp onto Nicolls Rd (CR 97 S). After 0.7 mile, turn right onto Purick Street then make a left onto Sylvan Avenue. School will be on the right.

Photo Ops: Ms. Malack-Ragona accepting the check from Ms. Gorman and the It Starts With Sylvan team members.

About Alzheimer’s Association

The Alzheimer's Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit www.alz.org.

Hank Russell, Public Relations Director
The Public Relations and Marketing Group
156 North Ocean Avenue
Patchogue, NY 11772
(631) 207-1057
hrussell@theprmg.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release MEDIA ADVISORY 4/3 "It Starts with Sylvan" Donates $1,000 towards 2012 Walk to End Alzheimer's here

News-ID: 216684 • Views:

More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as